Serum Institute of India, the world's biggest Covid-19 vaccine maker, is hopeful to launch Covovax by September this year, CEO Adar Poonawalla announced on Saturday.
"Covovax trials finally begin in India; the vaccine is made through a partnership with Novavax and Serum Institute of India," said Adar Poonawalla.
He further said that it has been tested against African and UK variants of Covid-19 and has an overall efficacy of 89 per cent. "Hope to launch by September 2021!" the CEO of world's biggest Covid-19 vaccine maker said.
Covovax is the protein-based Covid-19 vaccine developed by Novavax, headquartered in the US.
In August 2020, the two companies announced an agreement under which Novavax had given SII the licence to manufacture and supply the vaccine in low- and middle-income countries.
This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

Adar Poonawalla said that the vaccine has been tested against African and UK variants of Covid-19 and has an overall efficacy of 89 per cent.

Serum Institute's 2nd COVID-19 vaccine likely to be launched in September

Slandering judges on social media not acceptable: Ravi Shankar Prasad

Adar Poonawalla said that the vaccine has been tested against African and UK variants of Covid-19 and has an overall efficacy of 89 per cent,

Serum Institute's 2nd COVID-19 vaccine likely to be launched in September

Trending Stories

Latest Photos

Latest Videos

Latest Web Stories

Mid-Day Fast

Home / News / India News / Article / Serum Institute's 2nd COVID-19 vaccine likely to be launched in September

Serum Institute's 2nd COVID-19 vaccine likely to be launched in September

Trending Stories

Latest Photos

Latest Videos

Latest Web Stories

Mid-Day Fast